Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis - Mission possible?
George R Dakwar, Molood Shariati, Wouter Willaert, Wim Ceelen, Stefaan C De Smedt, Katrien Remaut, George R Dakwar, Molood Shariati, Wouter Willaert, Wim Ceelen, Stefaan C De Smedt, Katrien Remaut
Abstract
Intraperitoneal (IP) drug delivery represents an attractive strategy for the local treatment of peritoneal carcinomatosis (PC). Over the past decade, a lot of effort has been put both in the academia and clinic in developing IP therapeutic approaches that maximize local efficacy while limiting systemic side effects. Also nanomedicines are under investigation for the treatment of tumors confined to the peritoneal cavity, due to their potential to increase the peritoneal retention and to target drugs to the tumor sites as compared to free drugs. Despite the progress reported by multiple clinical studies, there are no FDA approved drugs or formulations for specific use in the IP cavity yet. This review discusses the current clinical management of PC, as well as recent advances in nanomedicine-based IP delivery. We address important challenges to be overcome towards designing optimal nanocarriers for IP therapy in vivo.
Keywords: Biodistribution; Intraperitoneal delivery; Nanomedicines; Peritoneal carcinomatosis; Sustained release.
Copyright © 2016 Elsevier B.V. All rights reserved.
Source: PubMed